CRCleonisio Leite Rodrigues

Cleonisio Leite Rodrigues

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cleonisio Leite Rodrigues has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neuropathy in Val122Ile Hereditary Transthyretin ( ATTR ) Amyloidosis: A Multicenter Retrospective Cohort Study

    by Anna Paula Paranhos, Marcela Câmara Machado Costa, Carolina Lavigne Moreira, Diogo Fernandes dos Santos, Marcondes Cavalcante França, Renan Flavio de França Nunes, Osvaldo José Moreira Do Nascimento, Jemima Araujo da Silva Batista, Eduardo Boiteux Uchôa Cavalcanti, Cleonisio Leite Rodrigues, et al.

    Background and Aims: The Val122Ile ATTR Amyloidosis has traditionally been linked to cardiac manifestations. Recent studies suggest that neuropathy may be relevant. In this study, we characterized its peripheral nerve manifestations in depth. Methods: This was a national, multicenter, observational, retrospective study. Patients underwent careful clinical and neurophysiological evaluation. We excluded those with alternative etiologies. Results: We identified 246 Val122Ile carriers, including 240 heterozygous, 4 homozygous, and 2 compound heterozygous. Gender distribution was similar. Age of onset: 19–89 years, mean 53 ± 17. Self‐reported ethnicity: White (26.7%), Black (17.3%), and Mixed (Pardo) (56.0%). Birthplaces spanned all Brazilian regions, mainly the Northeast. Among heterozygotes, 52 of 122 (42.6%) were symptomatic. Carpal tunnel syndrome (CTS) preceded polyneuropathy and/or cardiomyopathy in 69.2%. The most frequent onset manifestations, excluding CTS, were cardiomyopathy (52.9%), neuropathy (37.3%), and mixed phenotype (9.8%). Age of onset: 29–86 years (mean: 64.9 years). During follow‐up, 14/27 cardiac patients developed neuropathy, and 8/19 neurologic patients developed cardiomyopathy, significantly increasing the mixed phenotype from 9.8% to 52.9%. Most patients with neuropathy presented with sensory or sensory and motor disease (62.2%), followed by small fiber neuropathy (32.4%), and isolated dysautonomia (5.4%). Interpretation: Neuropathy is underrecognized in Val122Ile ATTR Amyloidosis, is frequent at disease onset, may be the sole manifestation, and may occur in White persons. CTS frequently preceded neuropathy, usually an axonal polyneuropathy, although atypical patterns were observed. This variant clusters in the Northeast region of Brazil.

  • Open Access

    Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems

    by José Pedro Soares Baima, Caio César Diniz Disserol, Eduardo Braga de Oliveira, Natália Merten Athayde, Lara Albuquerque de Brito, Hermany Capistrano Freitas, Cleonisio Leite Rodrigues

    Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.

  • Endothelial glycocalyx disruption and early renal tubular injury in hereditary transthyretin Amyloidosis with dysautonomia

    by Lara Albuquerque de Brito, Cleonisio Leite Rodrigues, Alexandre Braga Libório, Raynrich Kevin Assis Lima, Hermany Capistrano Freitas, Fernanda Martins Maia Carvalho

  • Open Access

    Peripheral Nerve Ultrasound Findings in Hereditary Transthyretin Amyloidosis in Brazil

    by Antonio Edvan Camelo-Filho, Anna Paula Paranhos Miranda Covaleski, Lara Albuquerque Brito, Cleonisio Leite Rodrigues, Ana Lucila Moreira

    Background/Objectives: Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant disorder characterized by systemic deposition of amyloid fibrils, leading to peripheral neuropathy and multisystemic involvement. Peripheral nerve ultrasound is a promising tool for detecting structural nerve changes, yet its use in Latin American populations is limited. This study aimed to characterize nerve ultrasound findings in Brazilian patients with ATTRv. Methods: We conducted a cross-sectional study of 72 genetically confirmed ATTRv individuals from two Brazilian centers. Participants were classified into symptomatic patients with polyneuropathy (n = 31) and asymptomatic TTR variant carriers (n = 41). All participants underwent a standardized neurological examination, and nerve ultrasound was used to assess the median nerve, brachial plexus, and C6 root. Cross-sectional areas (CSAs) from the right side were used for analysis and compared to reference values. Results: Symptomatic patients showed increased CSAs in the median nerve (wrist: 10.17 mm2, arm: 9.8 mm2), C6 root (8.55 mm2), and brachial plexus (70.82 mm2; all p < 0.05), but not in the forearm. Notably, asymptomatic carriers exhibited nerve enlargement in the median nerve at the wrist, the C6 root, and the brachial plexus, despite lacking clinical signs of neuropathy. Peripheral nerve enlargement in ATTRv affects both symptomatic patients and asymptomatic carriers, with a predilection for proximal and entrapment sites. Conclusions: These findings support the utility of nerve ultrasound as a non-invasive biomarker for early nerve involvement in ATTRv. Further studies are warranted to validate its role in disease monitoring and guide therapeutic interventions, especially in genetically at-risk populations.


  • Open Access

    Definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in amyotrophic lateral sclerosis (ALS): Consensus from ALS and Motor Neuron Disease Scientific Department of the Brazilian Academy of Neurology

    by Francisco de Assis Aquino Gondim, Wladimir Bocca Vieira de Rezende Pinto, Marco Antônio Troccoli Chieia, Carolina da Cunha Correia, Francisco Marcos Bezerra Cunha, Mário Emílio Teixeira Dourado Jr, Marcondes Cavalcante França Júnior, Wilson Marques Júnior, Acary Souza Bulle Oliveira, Cleonisio Leite Rodrigues, et al.

    The spectrum of neuropsychiatric phenomena observed in amyotrophic lateral sclerosis (ALS) is wide and not fully understood. Disorders of laughter and crying stand among the most common manifestations. The aim of this study is to report the results of an educational consensus organized by the Brazilian Academy of Neurology to evaluate the definitions, phenomenology, diagnosis, and management of the disorders of laughter and crying in ALS patients. Twelve members of the Brazilian Academy of Neurology - considered to be experts in the field - were recruited to answer 12 questions about the subject. After exchanging revisions, a first draft was prepared. A face-to-face meeting was held in Fortaleza, Brazil on 9.23.22 to discuss it. The revised version was subsequently emailed to all members of the ALS Scientific Department from the Brazilian Academy of Neurology and the final revised version submitted for publication. The prevalence of pseudobulbar affect/pathological laughter and crying (PBA/PLC) in ALS patients from 15 combined studies and 3906 patients was 27.4% (N = 1070), ranging from 11.4% to 71%. Bulbar onset is a risk factor but there are limited studies evaluating the differences in prevalence among the different motor neuron diseases subtypes, including patients with and without frontotemporal dementia. Antidepressants and a combination of dextromethorphan and quinidine (not available in Brazil) are possible therapeutic options. This group of panelists acknowledge the multiple gaps in the current literature and reinforces the need for further studies.


  • Open Access

    Letter response to “The Janus faces of SARS-COV-2 infection in myasthenia gravis and myasthenic crisis”

    by Paulo Ribeiro Nóbrega, Pedro Helder de Oliveira Junior, Hermany Capistrano de Freitas, José Artur Costa D’almeida, Cleonísio Leite Rodrigues

  • Open Access

    A rara associação de dermatomiosite secundária à Chikungunya em fase crônica

    by Natacha Campos Arriaga, Louise Cavalcanti Salles, Francisco Theogenes Macedo Silva, Fabrício André Martins da Costa, Cleonisio Leite Rodrigues, Kristopherson Lustosa Augusto

    A chikungunya é uma doença tropical infecciosa causada pelo vírus Chikungunya (CHIKV), um vírus de RNA da família Togaviridae, gênero Alphavirus. É transmitida por mosquitos do gênero Aedes, infectados com o CHIKV. A doença evolui em três fases: aguda, subaguda e crônica, esta última tendo início após 3 meses de sintomatologia. A mialgia é um dos sintomas mais prevalentes na doença podendo ser intensa. Na literatura, alguns casos de Miopatia secundária à Chikungunya em fase aguda foram descritos, porém poucos foram relatados na fase crônica da doença. Apresentamos o caso de uma paciente feminina, que em 2016 desenvolveu fraqueza muscular progressiva às custas de dermatomiosite após dois anos da infecção pelo CHIKV.